科恩-斯蒂尔斯金融 CNS 深 沪
已收盘 10-31 16:00:00 美东时间
68.32
-1.210
-1.74%
华盛通- 最 高69.19
- 今 开69.04
- 成交量 36.60万股
- 最 低 68.11
- 昨 收 69.53
- 总市值 34.84亿
- 52周最高 105.45
- 市盈率 静 23.01
- 换手率 0.00%
- 52周最低 64.29
- 委 比 0.00%
- 总股本 5099.67万
- 历史最高 108.22
- 量 比 1.07
- 振 幅 1.55%
- 历史最低 -4.89
- 每 手 1
- 风险率 9.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cohen & Steers, Inc. Declares Quarterly Dividend
NEW YORK, Oct. 30, 2025 /PRNewswire/ -- The Board of Directors of Cohen & Steers, Inc. (NYSE: CNS) declared a cash dividend for the fourth quarter of 2025 in the amount of $0.62 per share of...
10-31 04:22
Alpha Buying: When Insiders Buy Big & Why It Works in Every Market
Every market cycle has its own cast of optimists and skeptics. But few voices c...
10-30 22:57
Supernus a new buy at BofA on 'underappreciated' CNS assets
BofA Securities has initiated coverage of Supernus Pharmaceuticals (SUPN) at buy saying that the market is not fully appreciating the company's portfolio of central nervous system drugs. The bank set ...
10-30 02:37
Uncovering Potential: Alnylam Pharmaceuticals's Earnings Preview
Alnylam Pharmaceuticals (NASDAQ:ALNY) is gearing up to announce its quarterly e...
10-29 22:04
Rakovina Therapeutics Unveils AI-Developed ATR Inhibitors with CNS Penetration
The latest update is out from Rakovina Therapeutics Inc ( ($TSE:RKV) ). Rakovin...
10-27 16:32
Biogen's Immunology Pipeline Has Long-Term Potential: Analyst
Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across multiple immune diseases.
10-25 00:47
Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce
Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; Alector cuts 49% of staff.
10-23 00:07
Plus Therapeutics Expands CNSide Diagnostic Business, Lands National Coverage Deal With UnitedHealthcare
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers,
10-21 19:42
美股大行评级 | 潜在涨幅344.44%！Rani Therapeutics获Maxim Group升目标价至10美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Rani Therapeutics Hldgs"买入"评级，目标价从5美元升至10美元；韦德布什：维持Corbus Pharmaceuticals"跑赢大市"评级，目标价从31美元升至38美元
10-21 18:13
Evercore ISI Group Maintains Outperform on Cohen & Steers, Raises Price Target to $77
Evercore ISI Group analyst John Dunn maintains Cohen & Steers (NYSE:CNS) with a Outperform and raises the price target from $74 to $77.
10-21 00:51
